HBeAg-positive CHB patients with indeterminate phase associated with a high risk of significant fibrosis

The risk of liver fibrosis in HBeAg-positive chronic hepatitis B (CHB) patients with indeterminate phase is not well characterized. We aimed to compare the presence of liver fibrosis in HBeAg-positive CHB patients between indeterminate phase and immune-tolerant phase. This multi-center, retrospectiv...

Full description

Saved in:
Bibliographic Details
Published in:Virology journal 2024-11, Vol.21 (1), p.287-10, Article 287
Main Authors: Li, Yuanyuan, Zhu, Yijia, Gao, Dongmei, Pan, Yifan, Wang, Jian, Zhang, Shaoqiu, Yan, Xiaomin, Zhu, Li, Zhu, Chuanwu, Liu, Xingxiang, Zhang, Zhaoping, Li, Jie, Chen, Yuxin, Huang, Rui, Wu, Chao
Format: Article
Language:English
Subjects:
Adult
Alanine Transaminase - blood
Biopsy
Care and treatment
Chronic hepatitis B
Cirrhosis
Complications and side effects
Diagnosis
DNA, Viral - blood
Elasticity Imaging Techniques
Female
Fibrosis
HBV DNA
Health aspects
Hepatitis associated antigen
Hepatitis B
Hepatitis B e Antigens - blood
Hepatitis B virus - immunology
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - pathology
Humans
Immune-tolerant
Indeterminate phase
Liver
Liver - pathology
Liver cirrhosis
Liver Cirrhosis - pathology
Liver Cirrhosis - virology
Liver fibrosis
Male
Measurement
Middle Aged
Retrospective Studies
Risk factors
Viral Load
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The risk of liver fibrosis in HBeAg-positive chronic hepatitis B (CHB) patients with indeterminate phase is not well characterized. We aimed to compare the presence of liver fibrosis in HBeAg-positive CHB patients between indeterminate phase and immune-tolerant phase. This multi-center, retrospective cohort study included 719 treatment-naïve HBeAg-positive CHB patients with normal alanine aminotransferase (ALT). Patients with HBV DNA > 10 IU/mL were categorized into immune-tolerant phase, whereas those with HBV DNA ≤ 10 IU/mL were classified into indeterminate phase. Significant liver fibrosis and cirrhosis were determined by APRI, FIB-4, transient elastography, or liver biopsy. The median age of patients was 33.0 years and 59.8% of patients were male. 81.5% and 18.5% of patients were in the immune-tolerant phase and indeterminate phase, respectively. The APRI (0.33 vs. 0.27, P 
ISSN:1743-422X
1743-422X
DOI:10.1186/s12985-024-02561-1